Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians

Article Sidebar

PDF HTML
Published: Aug 3, 2023
DOI: https://doi.org/10.7196/AJTCCM.2023.v29i2.1231

Main Article Content

M S Moolla
Pulmonology Fellow, Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
A Doruyter
Consultant Nuclear Physician, NuMeRI Node for Infection Imaging, Central Analytical Facilities, Stellenbosch University, Cape Town, South Africa; Division of Nuclear Medicine, Department of Medical Imaging and Clinical Oncology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
B W Allwood
Consultant Pulmonologist, Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

Abstract

-

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Moolla MS, Doruyter A, Allwood BW. Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians. Afr J Thoracic Crit Care Med [Internet]. 2023 Aug. 3 [cited 2024 May 18];29(2):44-5. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/1231
Issue
AJTCCM Vol. 29 No. 2
Section
Editorials
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited. 

Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository. 

How to Cite

1.
Moolla MS, Doruyter A, Allwood BW. Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians. Afr J Thoracic Crit Care Med [Internet]. 2023 Aug. 3 [cited 2024 May 18];29(2):44-5. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/1231

References

Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J 2017;50(4). https://doi.org/10.1183/13993003.01209-2017

Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017;3:17074. https://doi.org/10.1038/nrdp.2017.74

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205(9):e18-e47. https://doi. org/10.1164/rccm.202202-0399st

WoltersPJ,BlackwellTS,EickelbergO,etal.Timeforachange:isidiopathicpulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med 2018;6(2):154-160.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, Group IPFCW. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51(5). https://doi.org/10.1183/13993003.00692-2018

The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. N Eng J Med 2012;366(21):1968-1977. https://doi.org/10.1056/nejmoa1113354

Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760- 1769. https://doi.org/10.1016/s0140-6736(11)60405-4

King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Eng J Med 2014;370(22):2083-2092. https://doi.org/10.1056/nejmoa1402582

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Eng J Med 2014;370(22):2071-2082. https://doi.org/10.1056/ nejmoa1402584

Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381(18):1718-1727.

Wuyts WA, Wijsenbeek M, Bondue B, et al. Idiopathic pulmonary fibrosis: Best practice in monitoring and managing a relentless fibrotic disease. Respiration 2020;99(1):73-82. https://doi.org/10.1159/000504763

Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013;107(12):2081-2087. https://doi. org/10.1016/j.rmed.2013.09.015

Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996;101(3):262-269. https:// doi.org/10.1016/s0002-9343(96)00155-6

Mora Cuesta VM, Iturbe Fernandez D, Gallardo Agromayor E, et al. Osteoporosis in lung transplant patients. European Resp J 2014;44(Suppl 58):P2456.

McQuiston A, Emtiazjoo A, Angel P, Machuca T, Christie J, Atkinson C. Set up for failure: pre-existing autoantibodies in lung transplant. Front Immunol 2021;12. https://doi.org/10.3389%2Ffimmu.2021.711102

Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014;33(5):514-520. https://doi. org/10.1016/j.healun.2014.01.858

Most read articles by the same author(s)